Dr Reddy's Labs launches Atomoxetine Capsules in US Market
Hyderabad: Dr. Reddy’s Laboratories Ltd. has recently announced the launch of Atomoxetine Capsules, USP, a therapeutic equivalent generic version of Strattera (atomoxetine) Capsules in the United States market approved by the U.S. Food and Drug Administration (USFDA).
The Strattera brand and generic had U.S. sales of approximately $304 million MAT for the most
recent twelve months ending in August 2018 according to IMS Health.
Straterra is a registered trademark of Eli Lilly and Company.
Read Also: Dr Reddy’s gets 8 observations from USFDA for Duvvada plant
The Strattera brand and generic had U.S. sales of approximately $304 million MAT for the most
recent twelve months ending in August 2018 according to IMS Health.
Atomoxetine is used to treat attention-deficit hyperactivity disorder (ADHD) as part of a total treatment plan, including psychological, social, and other treatments. It may help to increase the ability to pay attention, concentrate, stay focused, and stop fidgeting. It is thought to work by restoring the balance of certain natural substances (neurotransmitters) in the brain.
Dr. Reddy’s Atomoxetine Capsules, USP is available in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg 80
mg, 100 mg with 30 counts bottle size.
Straterra is a registered trademark of Eli Lilly and Company.
Read Also: Dr Reddy’s gets 8 observations from USFDA for Duvvada plant
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd